Search
Aceclidine
go.drugbank.com/drugs/DB13262ApprovedAceclidine is a cholinergic muscarinic agonist which began marketing in Europe in the 1970s for the treatment of glaucoma. … [A274278] Aceclidine was approved the US FDA in July 2025 for the treatment of adult patients with presbyopia.[L53768]
Categories: Cholinergic Receptor AgonistDoxazosin
go.drugbank.com/drugs/DB00590ApprovedInvestigational[A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285] … Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension.
Categories: Adrenergic alpha-1 Receptor AntagonistsDalteparin
go.drugbank.com/drugs/DB06779ApprovedInvestigationalDalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. … It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000.
Products: FRAGMIN 10000 IE, FRAGMIN 10000 IE FSBenzylpenicilloyl polylysine
go.drugbank.com/drugs/DB00895ApprovedInvestigationalThe quantitation of in vitro IgE antibodies to the benzylpenicilloyl determinant is a useful tool for evaluating allergic subjects. … Benzylpenicilloyl polylysine is used as a skin-testing reagent to detect immunoglobulin E antibodies in people with a history of penicillin allergy.
Human cord blood hematopoietic progenitor cell
go.drugbank.com/drugs/DB11054ApprovedUpon division and maturation at the bone marrow following intravenous administration to the patient, hematopoietic progenitor cells enter the systemic circulation to restore blood counts and function [ … bone marrow transplant setting, which may be due to "naive" nature of lymphocytes [A32223].
Anifrolumab
go.drugbank.com/drugs/DB11976ApprovedInvestigationalAnifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. … , which may alter patient responses in the experimental and placebo groups; and patient populations were largely homogenous, which may have increased the odds of success of the trial.
Categories: Type I Interferon Receptor AntagonistIcatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigationalrelief was observed to be 8 hours compared to 36 hours for the placebo treatment. … [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema.
Categories: Bradykinin Receptor Antagonists, Bradykinin B2 Receptor AntagonistsCetuximab
go.drugbank.com/drugs/DB00002ApprovedInvestigationalCetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor … [A227973] EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and homeostasis.
Categories: Epidermal Growth Factor Receptor Antagonist, EGFR (Epidermal Growth Factor Receptor) inhibitorsMethscopolamine bromide
go.drugbank.com/drugs/DB00462ApprovedA muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
Ferric oxide
go.drugbank.com/drugs/DB11576ApprovedInvestigationalIron(III) oxide or ferric oxide is the inorganic compound with the formula Fe2O3. … It is one of the three main oxides of iron, the other two being iron(II) oxide (FeO) the rarer form, and iron(II,III) oxide (Fe3O4) which naturally as magnetite.
Mixtures: OXIDO DE ZINC - CALAMINA UNGUENTO